Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PD-L1 inhibitors

- PMLiVE

Pfizer and Merck expand anti-PD1 cancer alliance

Will investigate combination of pembrolizumab and Xalkori

Bristol Myers Squibb logo

BMS and Celgene to research cancer immunotherapy combo

Companies will study combination of nivolumab and Abraxane

- PMLiVE

US talks tough on ‘unpatriotic’ tax inversion deals

Treasury looks to 'meaningfully reduce' tax benefits of such manoeuvres

EU flag

Politically acceptable – a unified patent for Europe

But will Europe’s Unified Patent Court help or harm the pharma sector?

- PMLiVE

European licence for BMS/Pfizer’s Eliquis in DVT and PE

Anticoagulant catches up with Bayer's Xarelto and Boehringer's Pradaxa

- PMLiVE

This month in 1989: the creation of Bristol-Myers Squibb

The emergence of a company with a new focus on healthcare and research

- PMLiVE

NICE backs cancer drugs from Astellas and BMS

Recommendations for Xtandi in prostate cancer and earlier use of Yervoy

- PMLiVE

Cancer drug nivolumab wins PD1 inhibitor race to market

BMS and Ono’s skin cancer treatment approved in Japan under trade name Opdivo

- PMLiVE

Japan first to approve Roche’s lung cancer drug alectinib

Personalised medicine has same target as Pfizer’s Xalkori and Novartis’ Zykadia

- PMLiVE

MSD’s Kate Tillett rewarded for healthcare comms excellence

Company's external affairs director wins at Communiqué 2014

Bristol-Myers Squibb (BMS) building

BMS to publish full clinical study reports in transparency drive

Partners with Duke University to grant access back to 2008

- PMLiVE

Merck KGaA drops Ono-partnered multiple sclerosis drug

Decides phase III candidate ceralifimod isn't worth its continued investment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links